How to Eat on Retatrutide: Trial Data

How to eat on retatrutide is a question arising from clinical trial data, not from any authorised prescribing guidance. Retatrutide is an investigational triple hormone receptor agonist, acting on GIP, GLP-1 and glucagon receptors, with no marketing authorisation in the UK or elsewhere. It is available only to participants enrolled in authorised clinical trials such as the TRIUMPH and TRANSCEND programmes. This article outlines what trial data report about appetite and digestion, the gastrointestinal side effects observed, and why retatrutide cannot be accessed outside a formal study protocol in the UK.

What is retatrutide and what stage is it at in the UK?

Retatrutide is an investigational GIP, GLP-1 and glucagon triple receptor agonist with no UK marketing authorisation; it is accessible only within authorised clinical trials such as TRIUMPH and TRANSCEND.

Retatrutide is an investigational medicine with no marketing authorisation in the UK or anywhere else, meaning it cannot be prescribed or supplied outside an authorised clinical trial.^[1][2] It is a triple hormone receptor agonist, acting on GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors simultaneously. This triple mechanism distinguishes it pharmacologically from currently licensed treatments, though no head-to-head comparisons with authorised medicines have been confirmed in the published literature to date.

Clinical investigation has progressed beyond Phase 2. Phase 2 data were published in the New England Journal of Medicine in 2023, and the Phase 3 programme, which includes the TRIUMPH and TRANSCEND trials, is under way.^[1][2] Some Phase 3 readouts have been reported, including data from the TRANSCEND-T2D-1 study and elements of the TRIUMPH programme presented at major diabetes and obesity congresses.^[3][4] These findings are preliminary in the context of the full regulatory evidence package and should be interpreted cautiously; they do not alter the medicine's investigational status.

The larger Phase 3 trials are designed to generate the safety and efficacy evidence that regulatory bodies such as the MHRA would require before considering a marketing authorisation application. Trial registries such as ClinicalTrials.gov hold current information on the TRIUMPH and TRANSCEND studies for those seeking programme details.

Because retatrutide holds no UK licence, it is not available through NHS or private prescribing routes. It can be accessed only by participants enrolled in an authorised clinical trial under a formal study protocol. No timeline for any potential UK authorisation can be given, and none should be assumed. If you are interested in licensed weight-management treatments, your GP can discuss options that are currently available.

What did clinical trials report about appetite and eating patterns?

The Phase 2 trial (NEJM, 2023) reported reduced appetite and food intake, but no official dietary guidelines for retatrutide exist outside the structured support provided within trial protocols.

In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving retatrutide reported substantial reductions in appetite and food intake over the 48-week study period.^[1][2] These findings are specific to the trial population, which comprised adults with obesity or overweight and associated health conditions, and they reflect outcomes within a controlled research setting rather than predictions of individual experience. Individual responses varied across the trial population.

The GLP-1 receptor agonist component of retatrutide slows gastric emptying, which prolongs the sensation of fullness after eating.^[11][12] This effect is generally most pronounced early in treatment and may attenuate with continued use. The GIP and glucagon receptor activity may further influence energy regulation and satiety signalling. Together, these mechanisms are thought to contribute to reduced caloric consumption, though the precise contribution of each receptor pathway in humans continues to be studied.

Because retatrutide is not an authorised medicine, there are no official dietary guidelines, meal plans or eating recommendations associated with its use outside a trial. Within a clinical trial, participants receive structured dietary and lifestyle support as part of the study protocol, and any guidance on eating patterns comes from the trial team rather than from a product label or prescribing information. It would not be appropriate to extrapolate trial dietary frameworks as general advice, and no such framework exists in the public domain for retatrutide specifically.

Are there known side effects linked to food intake or digestion?

Nausea, vomiting, diarrhoea and constipation were commonly reported in Phase 2 data; fatty or large meals can worsen nausea, and trial teams advise smaller, lower-fat portions within the study protocol.

The Phase 2 trial of retatrutide reported that gastrointestinal side effects were among the most commonly observed findings, consistent with the GLP-1 receptor agonist class of medicines. These included nausea, vomiting, diarrhoea and constipation, and they were generally more frequent at higher doses and during dose escalation periods.

Nausea in particular is closely linked to eating patterns in this drug class. Fatty, rich or large meals can worsen nausea, and trial participants are typically advised by the study team to eat smaller portions, choose lower-fat foods and eat slowly. However, these are general principles applied within the trial protocol and are not published dietary instructions for retatrutide as a product.

The UK SmPC for licensed GLP-1-containing medicines notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, though no risk magnitude is established.^[14][15] As retatrutide shares this receptor activity, the trial safety monitoring includes assessment for pancreatic events. Participants in the TRIUMPH and TRANSCEND trials who experience persistent severe abdominal pain should report this to their trial team immediately under the study protocol.

Gallbladder-related events, including gallstones, have also been observed with medicines in this class. Rapid weight loss of any cause can increase gallstone risk. Within a trial, these events are monitored and reported according to the study protocol.

Clinical trials in this drug class typically exclude participants who are pregnant or breastfeeding, and effective contraception is usually required throughout participation. If a participant becomes pregnant during a trial, they should contact their trial team immediately, as the study protocol will specify the required steps.

Participants with known diabetic retinopathy, particularly pre-proliferative or proliferative retinopathy, should inform their trial team, as this subgroup has been identified as being at higher risk of retinopathy-related events with medicines in this class.

Before any surgical or dental procedure requiring anaesthesia or sedation, participants should inform the anaesthetist or treating clinician that they are taking part in a trial involving a GLP-1 receptor agonist, and should follow their trial team's instructions on whether to withhold the medicine beforehand. This is consistent with MHRA Drug Safety Update guidance on aspiration risk in this drug class.

Suspected side effects should be reported to the trial team as the primary route within a clinical trial. Outside a trial context, suspected side effects of medicines can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Why can't I access retatrutide outside a clinical trial in the UK?

Retatrutide has not received MHRA marketing authorisation, so it cannot be prescribed through NHS or private routes and remains available only to participants in authorised clinical trials.

Retatrutide cannot be prescribed or supplied outside an authorised clinical trial in the UK because it has not received a marketing authorisation from the MHRA. Before any medicine can be authorised, the manufacturer must submit a comprehensive dossier of evidence covering quality, safety and efficacy. The MHRA then evaluates that evidence against established standards before deciding whether to grant authorisation. Retatrutide has not yet completed that process.

The Phase 3 TRIUMPH and TRANSCEND trials are generating the large-scale, long-term data that would form the basis of any future regulatory submission. Until those data are fully reviewed and a decision is made, the medicine remains investigational. This is a standard and necessary part of medicines regulation, designed to protect patients from treatments whose full risk and benefit profile is not yet established.

NICE does not recommend medicines for NHS use until they hold a marketing authorisation, and local Integrated Care Boards (ICBs) commission treatments based on NICE guidance and local clinical priorities.^[22][23] Retatrutide therefore sits entirely outside NHS commissioning at this stage. Private prescribing is equally unavailable: as an investigational pipeline medicine, retatrutide is not accessible through private prescribing routes in the UK, and access is limited to participation in an authorised clinical trial.

If you are seeking support for weight management now, licensed options exist and your GP is the appropriate starting point for a clinical assessment and discussion of what may be suitable for you.

What are the risks of buying retatrutide online without a prescription?

Any retatrutide sold online is not a licensed product and may be falsified, contaminated or incorrectly dosed; there is no legitimate commercial supply chain and purchase outside a trial is unlawful.

Any retatrutide offered for sale online is not a licensed medicine and may be a falsified, counterfeit or incorrectly manufactured product. Because retatrutide holds no marketing authorisation anywhere in the world, there is no legitimate commercial supply chain for it.^[1][2] Websites or individuals claiming to sell it are operating outside the law, and the substance being sold cannot be verified as safe, pure or correctly dosed.

Falsified medicines sold online have been found to contain incorrect active ingredients, harmful contaminants, or no active substance at all. Injecting an unverified substance carries serious risks including infection, allergic reaction and unpredictable pharmacological effects. There is no clinical oversight, no dose escalation protocol and no monitoring for adverse events when a product is obtained this way.

In the UK, legitimate distance-selling pharmacies are registered with the General Pharmaceutical Council (GPhC), which maintains a public register at pharmacyregulation.org. In Northern Ireland, the Pharmaceutical Society of Northern Ireland (PSNI) holds the equivalent register at psni.org.uk. However, registration with these bodies does not make the supply of an unlicensed investigational medicine lawful, and no registered pharmacy can legally supply retatrutide outside a clinical trial.

If you encounter websites promoting retatrutide as available for purchase, or if you are approached with offers of it online, you can report this to the MHRA using the reporting channels on the MHRA website at gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency. Protecting yourself means relying only on medicines that have been through proper regulatory review and are supplied through authorised, verifiable routes.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (PubMed record, N Engl J Med 2023).
3. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist — TRANSCEND-T2D-1.
4. Retatrutide, a Triple Hormone Receptor Agonist, for Obesity — Phase 3 trial (TRIUMPH programme).
5. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide.
6. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — phase 2 trial.
7. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide — phase 2 study.
8. Advances in the management of obesity: non-pharmacological strategies, pharmacotherapy, emerging drugs (includes triple receptor agonist pharmacology).
9. Cardiovascular effects of incretin receptor agonists: beyond glycemic control.
10. Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.
11. Insights into Natural Dietary Components as Indirect Modulators of GLP-1 Receptor Signaling in Weight Management.
12. Digestive Hormones and Their Impact on Bariatric and Pharmacologic Weight-Loss Therapies.
13. Exploring the off-label use of liraglutide in the treatment of obesity: a review.
14. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
15. Ozempic 0.5 mg solution for injection in pre-filled pen — Summary of Product Characteristics.
16. Association of GLP-1 Receptor Agonist Use with Gallbladder and Biliary Diseases.
17. GLP-1 Receptor Agonists and Sight-Threatening Diabetic Retinopathy.
18. Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.
19. Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes.
20. Semaglutide — eye-catching results.
21. GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation.
22. Guide to the processes of technology appraisal.
23. About technology appraisal guidance.
24. Introducing new medicines in the NHS in the UK — pathway.
25. General Pharmaceutical Council (GPhC) — pharmacy register.
26. Pharmaceutical Society of Northern Ireland (PSNI) — pharmacy register.

Frequently Asked Questions